← FDA DRUG APPROVALS

FDA ANDA · ANDA206939

CEFIXIME

Sponsor: AJENAT PHARMS

APPLICATION
ANDA206939
TYPE
ANDA
ORIGINAL APPROVAL
2017-02-06
LATEST ACTION
2017-02-06
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

CEFIXIMEPrescription
CEFIXIME 500MG/5ML · FOR SUSPENSION · ORAL

Approval history

2017-02-06UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →